Skip to main content
construction release_alert
Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements. More information about the transition.
cancel

Nirmish Ramesh Shah

Associate Professor of Medicine
Medicine, Hematology
Department of Medicine, Duke S, Durham, NC 27710
Department of Medicine, Duke S, Durham, NC 27710

Current Appointments & Affiliations


Associate Professor of Medicine · 2024 - Present Medicine, Hematology, Medicine
Associate Professor in Pediatrics · 2019 - Present Pediatrics, Hematology-Oncology, Pediatrics

Recent Publications


Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries.

Journal Article Blood Adv · May 12, 2026 Two registry studies, RETRO and PROSPECT, were conducted to evaluate real-world safety and effectiveness outcomes in US participants with sickle cell disease (SCD) who received voxelotor as standard of care. RETRO collected retrospective data of participan ... Full text Link to item Cite

Sustainment of Hydroxyurea Adherence in Patients With Sickle Cell Disease.

Journal Article JAMA Netw Open · May 1, 2026 IMPORTANCE: Despite established treatment guidelines and strong therapeutic benefit, hydroxyurea remains underused among patients with sickle cell disease. OBJECTIVE: To assess the change in self-reported hydroxyurea use (ie, taking the medication at all) ... Full text Link to item Cite

Pre-implementation Barriers and Facilitators to Integrating Complementary and Integrative Health Interventions into Clinic Workflow: The GRACE Trial, NIH Pragmatic Trials Collaboratory.

Journal Article Pain Manag Nurs · January 20, 2026 BACKGROUND: Even though there is clear evidence supporting the use of complementary and integrative health (CIH) interventions for chronic pain, their integration into clinical care is challenging. Thus, the purpose of this study was to understand how the ... Full text Link to item Cite
View All Publications

Recent Grants


The efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA)

Clinical TrialPrincipal Investigator · Awarded by Sanofi US Services, Inc. · 2026 - 2030

Nurse LEADS: Training in Nurse-LEd models of care ADdressing the Social Determinants of Health

Inst. Training Prgm or CMEMentor · Awarded by National Institute of Nursing Research · 2024 - 2029

GBT021601-021

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2026 - 2028

View All Grants

Education


American University of the Caribbean · 2000 M.D.